Perinatal EvidenceCompass
Prepopulated workbenchMED-232

Substance-use disorder — alcohol

Varenicline

Approved or off-label medication considered in alcohol use disorder

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Varenicline
Entity type
single-ingredient drug
Active component(s)
Varenicline
Formulation / route / interval
Oral; formulation varies
Attachment entry
Varenicline
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Also: nicotine dependence and alcohol-use-disorder research
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

5 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-013Provisional public source

No AUD pharmacotherapy has a large pregnancy-specific efficacy-and-safety evidence base comparable to OUD agonist treatment; continued heavy alcohol exposure itself is a major maternal-fetal hazard.

Public-source certainty descriptor
Moderate guideline consensus; low drug-specific pregnancy evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Preconception through postpartum
Comparator
Medication plus care versus continued AUD or psychosocial care alone
Effect or numbers carried forward

No pooled pregnancy efficacy estimate

Limitations

Medication cohorts are small and confounded; the risk of untreated severe AUD varies greatly

Sources, citation controls, and verification state

Linked sources

PMID
33830479
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-018Provisional public source

Ondansetron and varenicline have been studied for alcohol outcomes in selected nonpregnant populations, but neither should be initiated as routine AUD pharmacotherapy in pregnancy.

Public-source certainty descriptor
Low for AUD; high indication certainty
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy
Comparator
Off-label AUD use versus established AUD care
Effect or numbers carried forward

No pregnancy AUD efficacy estimate

Limitations

Pregnancy safety evidence for their approved uses does not establish AUD effectiveness

Sources, citation controls, and verification state

Linked sources

PMID
33830479
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-019Provisional public source

Severe alcohol withdrawal in pregnancy is a medical emergency; benzodiazepines may be required despite reproductive uncertainty because seizure, delirium and autonomic instability threaten patient and fetus.

Public-source certainty descriptor
High emergency consensus; low pregnancy trial evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Acute withdrawal
Comparator
Supervised medication treatment versus untreated withdrawal
Effect or numbers carried forward

No randomized pregnancy withdrawal comparison; treatment is risk-based

Limitations

Specific regimen depends on severity, gestation and comorbidity; not a home-detox protocol

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-021Provisional public source

A 2025 multinational cohort found no clear overall major-congenital-malformation increase with first-trimester varenicline, bupropion or NRT compared with smoking, but it does not establish pregnancy cessation efficacy or exclude uncommon risks.

Public-source certainty descriptor
Moderate-low; large observational study
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
First trimester
Comparator
Cessation medicines versus smoking in pregnancy
Effect or numbers carried forward

No clear overall MCM elevation in studied exposure groups

Limitations

Residual confounding, adherence uncertainty and limited power for specific defects

Sources, citation controls, and verification state

Linked sources

PMID
40163085
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-022Provisional public source

An observational 2025 study suggested greater smoking-cessation effectiveness with varenicline than NRT in pregnancy, but nonadherence and unmeasured confounding limit causal interpretation.

Public-source certainty descriptor
Low-to-moderate; observational
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy
Comparator
Varenicline versus NRT
Effect or numbers carried forward

Direction favored varenicline; no causal estimate adopted for this manual

Limitations

Not randomized; treatment selection and adherence likely differ

Sources, citation controls, and verification state

Linked sources

PMID
41424159
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending